M
Martin S. Tallman
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 948
Citations - 71451
Martin S. Tallman is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 117, co-authored 917 publications receiving 60011 citations. Previous affiliations of Martin S. Tallman include University of Rome Tor Vergata & University of Toronto.
Papers
More filters
Journal ArticleDOI
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.
Michael Boyiadzis,Michael R. Bishop,Rafat Abonour,Kenneth C. Anderson,Stephen M. Ansell,David Avigan,Lisa Barbarotta,Austin John Barrett,Koen van Besien,P. Leif Bergsagel,Ivan Borrello,Joshua Brody,Jill Brufsky,Mitchell S. Cairo,Ajai Chari,Adam D. Cohen,Jorge E. Cortes,Stephen J. Forman,Jonathan W. Friedberg,Ephraim J. Fuchs,Steven D. Gore,Sundar Jagannath,Brad S. Kahl,Justin Kline,James N. Kochenderfer,Larry W. Kwak,Ronald Levy,Marcos de Lima,Mark R. Litzow,Anuj Mahindra,Jack M. Miller,Nikhil C. Munshi,Robert Z. Orlowski,John M. Pagel,David L. Porter,Stephen J. Russell,Karl Schwartz,Margaret A. Shipp,David S. Siegel,Richard Stone,Martin S. Tallman,John M. Timmerman,Frits van Rhee,Edmund K. Waller,Ann Welsh,Michael Werner,Peter H. Wiernik,Madhav V. Dhodapkar +47 more
TL;DR: In 2014, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia.
Journal ArticleDOI
Identification of a Second Acute Promyelocytic Leukemia (APL) Patient with the STAT5b-RARα Fusion Gene among PML-RARα-Negative Eastern Cooperative Oncology Group (ECOG) APL Protocol Registrants.
Robert E. Gallagher,Serena Mak,Elisabeth Paietta,Brenda W. Cooper,W. Christopher Ehmann,Martin S. Tallman +5 more
Journal ArticleDOI
BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial
Gautam Borthakur,Arnon Nagler,Yishai Ofran,Jacob M. Rowe,Jessica K. Altman,Olga Frankfurt,Martin S. Tallman,Irit Avivi,Amnon Peled,Yaron Pereg,Adam Foley-Comer,Lena Russovsky,Arnon Aharon,Teresa McQueen,Naveen Pemmaraju,Carlos E. Bueso-Ramos,Jorge E. Cortes,Michael Andreeff +17 more
TL;DR: Preliminary results from the ongoing study suggest that administration of BL-8040, in combination with Ara-C, is safe and well tolerated at all doses tested to date and the safety and tolerability, pharmacokinetic profile and clinical responses are being evaluated.
Journal ArticleDOI
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
Justin Taylor,Xiaoli Mi,Alexander V Penson,Stella V Paffenholz,Kelsey Alvarez,Allison Sigler,Stephen S. Chung,Raajit K. Rampal,Jae H. Park,Eytan M. Stein,Martin S. Tallman,Filiz Sen,Mithat Gonen,Omar Abdel-Wahab,Virginia M. Klimek +14 more
TL;DR: Selinexor showed responses in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents, and further studies are needed to compare selinexor with supportive care alone, and to identify patient subgroups that might benefit the most from se linexor treatment.
Journal ArticleDOI
Predictive factors of fatal bleeding in acute promyelocytic leukemia.
TL;DR: Elevated white blood cell count at presentation is the main predictor of early hemorrhagic death and early thrombo-hemorrhagic death in APL, respectively.